ATLANTA--(BUSINESS WIRE)--June 5, 2006--MGI PHARMA, INC. (Nasdaq:MOGN - News), an oncology- and acute care-focused biopharmaceutical company, today provided a summary of Aloxi® (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine implant) presentations made during the 2006 American Society of Clinical Oncology (ASCO) Annual Meeting. In addition, MGI PHARMA sponsored a Corporate Friday symposium titled Harnessing the Therapeutic Potential of Epigenetics, which was chaired by Dr. Stephen Baylin of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The Company also announced that enrollment is now complete in its multi-center phase 2 alternate dosing trial of Dacogen in patients with myelodysplastic syndromes (MDS). This trial, called ADOPT (Alternate Dosing for Outpatient Treatment), is designed to evaluate a 5 day Dacogen dosing regimen of intravenous one hour infusions at a dose of 20 mg/m(2).
